by Mihai | Jun 2, 2026 | Uncategorized
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary...
by Alexandra | Oct 26, 2024 | Uncategorized
Advanced Nanotherapies Announces Positive Results in its First-in-Human Trial And Plans for U.S. Early Feasibility Study for Sirplux™ Duo Drug-Coated Balloon First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase Novel...
by Mihai | Aug 22, 2023 | Uncategorized
Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating de novo Coronary Artery Disease (CAD) Milestone achieved as company announces successful enrollment of ten patients...
by Alexandra | Sep 19, 2022 | Uncategorized
Advanced NanoTherapies’ SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease Breakthrough Designation Reinforces Significant Unmet Need in Treatment of Small Vessel Coronary Arteries LOS GATOS, CA – September...
by Mihai | Jun 28, 2022 | Uncategorized
Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing Funds to support the first-in-human clinical study of the company’s SirPluxTM Duo Drug-Coated Balloon for the treatment of de-novo coronary artery disease LOS GATOS, CA – June...
by Dora | Jan 10, 2022 | Uncategorized
SirPlux Duo Receives Breakthrough Designation On May 28, 2021, the US Food and Drug Administration (FDA) granted Advanced NanoTherapies Breakthrough Designation for its SirPlux Duo device. SirPlux Duo is a drug-coated balloon (DCB) that leverages nanotechnology to...
